Notice2024-07905
Foreign-Trade Zone (FTZ) 224; Notification of Proposed Production Activity; Jubilant HollisterStier, LLC; (Pharmaceuticals) Spokane, Washington
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
April 15, 2024
Issuing agencies
Commerce DepartmentForeign-Trade Zones Board
Full Text
<html>
<head>
<title>Federal Register, Volume 89 Issue 73 (Monday, April 15, 2024)</title>
</head>
<body><pre>
[Federal Register Volume 89, Number 73 (Monday, April 15, 2024)]
[Notices]
[Page 26125]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2024-07905]
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
Foreign-Trade Zones Board
[B-15-2024]
Foreign-Trade Zone (FTZ) 224; Notification of Proposed Production
Activity; Jubilant HollisterStier, LLC; (Pharmaceuticals) Spokane,
Washington
Jubilant HollisterStier, LLC, submitted a notification of proposed
production activity to the FTZ Board (the Board) for its facility in
Spokane, Washington within FTZ 224. The notification conforming to the
requirements of the Board's regulations (15 CFR 400.22) was received on
April 9, 2024.
Pursuant to 15 CFR 400.14(b), FTZ production activity would be
limited to the specific foreign-status material(s)/component(s) and
specific finished product(s) described in the submitted notification
(summarized below) and subsequently authorized by the Board. The
benefits that may stem from conducting production activity under FTZ
procedures are explained in the background section of the Board's
website--accessible via <a href="http://www.trade.gov/ftz">www.trade.gov/ftz</a>.
The proposed finished product is cetuximab finished drug product
(duty free).
The proposed foreign-status materials/components include cetuximab
monoclonal antibody active pharmaceutical ingredient (API) in mixed and
unmixed forms (duty free).
Public comment is invited from interested parties. Submissions
shall be addressed to the Board's Executive Secretary and sent to:
<a href="/cdn-cgi/l/email-protection#99ffede3d9edebf8fdfcb7fef6ef"><span class="__cf_email__" data-cfemail="5432202e1420263530317a333b22">[email protected]</span></a>. The closing period for their receipt is May 28, 2024.
A copy of the notification will be available for public inspection
in the ``Online FTZ Information System'' section of the Board's
website.
For further information, contact Diane Finver at
<a href="/cdn-cgi/l/email-protection#6a2e030b040f442c03041c0f182a1e180b0e0f440d051c"><span class="__cf_email__" data-cfemail="c88ca1a9a6ade68ea1a6beadba88bcbaa9acade6afa7be">[email protected]</span></a>.
Dated: April 10, 2024.
Elizabeth Whiteman,
Executive Secretary.
[FR Doc. 2024-07905 Filed 4-12-24; 8:45 am]
BILLING CODE 3510-DS-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on April 15, 2024.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.